louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00177190: In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
Official title: In Vitro Evaluation of Immune Responses in CTCL
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cutaneous T-cell Lymphoma
Sezary Syndrome
Mycosis Fungoides
Keywords: Cutaneous T-cell Lymphoma
Sezary Syndrome
Mycosis Fungoides
Immune Responses
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
First posted: 2005-09-15
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cutaneous Lymphoma Clinic patients

Brief summary: This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.

Detailed description: This is an in vitro evaluation of cutaneous T-cell lymphoma using patients blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/ CD 8 cells with the following objectives:

* Objective I: Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8 and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma (CTCL) and Sezary syndrome (leukemic stage of CTCL) undergoing an approved FDA therapy, extracorporeal photopheresis (ECP).
* Objective II: Evaluate antigen loading of the DCs.
* Objective III: Test the functional capacities of the DCs derived from CTCL subjects to overcome immune tolerance to the tumor cells ex-vivo, by using modified Elispot assay in conjunction with Granzyme B Elispot assay as a measurement of cytotoxicity.

Eligibility criteria: Inclusion Criteria:

* Males or females \<18 years of age
* Histologically confirmed stage IV cutaneous T-cell lymphoma, with at least 5% of the peripheral blood lymphocytes showing atypical morphology consistent with Sezary cells
* Ambulatory and be in stable medical condition
* Biopsy positive mycosis fungoides/CTCL or clonal type of CTCL as determined by PCR for TCR and Southern blot for TCR

Exclusion Criteria:

* Received any chemotherapy or radiotherapy within 4 weeks prior to enrollment
* Significant psychiatric illness which would prevent adequate informed consent in the opinion of the principal investigator
* Systemic steroid therapy other than maintenance for adrenal suppression
* Known coagulopathy for non SS subjects.

Primary outcomes:
measure: Functional capacity of dendritic cells in-vitro
timeFrame: At each cell collection
Secondary outcomes:
measure: Evaluate antigen loading of dendritic cells
timeFrame: At each cell collection
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
affiliation: University of Pittsburgh
name: Larisa J. Geskin, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03930290: Physiologic Elasticity Changes During Pregnancy and After Labor.
Official title: Vaginal Tactile Imaging for the Assessment of Physiologic Elasticity Changes During Pregnancy and After Labor.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Vaginal Prolapse
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2019-04-29
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant patients in their 2nd trimester with no regard to previous obstetric history.

Brief summary: Female pregnant patients in their 2nd trimester will be evaluated for vaginal elasticity using vaginal tactile imaging in addition to elasticity evaluation during the 3rd trimester and 6 weeks postpartum.

Detailed description: Female pregnant patients in their 2nd trimester will be evaluated for vaginal elasticity using vaginal tactile imaging. Vaginal elasticity will also be evaluated during the 3rd trimester and 6 weeks postpartum.

Patients will be recruited and sign a consent form. Assessment of vaginal elasticity via vaginal tactile imaging will be performed at 3 different points:

* During the 2nd trimester.
* During the 3rd trimester.
* 6 weeks postpartum. Every patient will serve as her own control. Demographic, gynecologic and obstetric history will be obtained from patients' electronic files.

Eligibility criteria: Inclusion Criteria:

* Pregnant patients in their 2nd trimester.

Exclusion Criteria:

* Pregnant patients presenting after their 2nd trimester.

Primary outcomes:
measure: Vaginal elasticity
timeFrame: From the beginning of the 2nd trimester of pregnancy up to 6 weeks postpartum.
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam health care campus
Study officials:
affiliation: Rambam healthcare campus
name: Roy Lauterbach, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03503890: Expanded Access to Rovalpituzumab Tesirine
Official title: Expanded Access to Rovalpituzumab Tesirine
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Small Cell Lung Cancer
Keywords: Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2018-04-20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Rovalpituzumab Tesirine prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.


Eligibility criteria: Inclusion Criteria:

* The participant must not be eligible for a Rovalpituzumab Tesirine clinical trial.
* Pediatric participants may be evaluated on a case by case basis.

Exclusion Criteria:

* None.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: AbbVie Inc.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00300690: Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp)
Official title: Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Intermittent Claudication
Critical Limb Ischemia
Keywords: Lower extremity bypass surgery
femoro-popliteal bypass
Dacron material
PTFE material
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
Collaborators: name: B. Braun Melsungen AG
First posted: 2006-03-09
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial was designed to challenge the wide held view that polytetrafluoroethylene (PTFE) performs better than Dacron for above knee femoropopliteal bypass.

Detailed description: Objective: To investigate whether patency rates of 6 mm gelatine coated, knitted, double velour polyester prostheses are equal to the 6 mm thinwalled ePTFE prostheses as above-knee femoro-popliteal bypass graft

Eligibility criteria: Inclusion Criteria:

* All patients who require revascularisation of the lower extremity suitable for above-knee femoro-popliteal bypass surgery.

Exclusion Criteria:

* pregnancy
* No consent to participate in the study
* Previous enrollment in the study
* follow-up is not possible

Primary outcomes:
measure: Primary uncorrected graft patency after 2 years
Secondary outcomes:
measure: - Secondary graft patency after two years
measure: - Limb survival after two years
measure: - Complication rate perioperatively
Other outcomes:
Locations:
Study officials:
affiliation: Rigshospitalet, Denmark
name: Torben V Schroeder, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04103190: Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor)
Official title: Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Benign Neuronal Desease
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2019-09-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patient supported for suspicion of MVNT

Brief summary: Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor), low-grade gliomas, cortical dysplasias or even hamartomas.

Detailed description: Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor), low-grade gliomas, cortical dysplasias or even hamartomas.

However, in order to avoid an invasive surgical procedure to remove the lesion, a certain diagnosis of its benignity is essential. The contribution of advanced techniques in MRI, such as spectroscopy in the characterization of these lesions, has not yet been studied today

Eligibility criteria: Inclusion Criteria:

* Patient over 18 years old
* Suspicion of MVNT on an MRI: it is considered that it will be necessary at least the 2 major criteria associated with at least 1 minor criterion to enter the definition of suspicion of MVNT:

Major criteria:

* Multinodular aspect in cluster
* High FLAIR hypersignal / T2

Minor criteria:

* Absence of mass effect
* Hyposignal T1
* Center of the lesion in hypsignal FLAIR or T1 hypersignal

  * Affiliate or beneficiary of a Social Security scheme
  * Having received informed information about the study and consenting to participate in the study

Exclusion Criteria:

* Patient benefiting from a legal protection measure
* Pregnant or lactating woman
* Contraindication to MRI

Primary outcomes:
measure: Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)
timeFrame: 1 day
measure: Description of a new radiological entity on Spectroscopy : the MVNT (Multinodular and Vacuolating Neuronal Tumor)
timeFrame: 1 day
measure: Description of a new radiological entity on Spectroscopy : : the MVNT (Multinodular and Vacuolating Neuronal Tumor)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Groupe Hospitalier Pellegrin
city: Paris
country: France
facility: Fondation Adolphe de Rothschild
city: Pierre Bénite
country: France
facility: Centre Hospitalier Lyon Sud
city: Rennes
country: France
facility: CHU Rennes
city: Rouen
country: France
facility: CHU de Rouen
city: Saint-Herblain
country: France
facility: Hôpital Laennec
city: Toulouse
country: France
facility: Hôpital Pierre Paul Riquet, CHU Purpan
Study officials:
References:
Clinical trial NCT06824090: Tonus, Stiffness and Elasticity of Hand and Wrist Muscles in Smartphone Addiction
Official title: Investigation of Tonus, Stiffness and Elasticity of Hand and Wrist Muscles in Intensive Smartphone Use
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Muscle Biomechanics
Smartphone Addisction
Keywords: smartphone
tonus
stiffness
elasticity
Lead sponsor: Bandırma Onyedi Eylül University
Sponsor class: OTHER
First posted: 2025-02-13
Enrollment: 56
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: University students

Brief summary: The aim of this study was to investigate the tonus, stiffness and elasticity of the hand and wrist muscles in intensive smartphone use.

Detailed description: Consent was obtained from the students with the 'Informed Voluntary Consent Form' and the sociodemographic data of the students were recorded on the previously prepared Descriptive Data Form. The students were asked to fill out the Smartphone Addiction Scale-Short Form. Before starting the clinical evaluation, anamnesis was taken from the students and their general health status, phone usage time (minutes) and exclusion criteria were questioned. Myotone evaluations of the tenar region, flexor carpi radialis, flexor carpi ulnaris, extensor digitorum, extensor carpi radialis and extensor carpi ulnaris muscles were performed. Then, the standard grip strength of the dominant and non-dominant side hand was evaluated with Saehan hand dynamometer and the lateral grip strength of the thumb was evaluated with Saehan pinchmeter.

Eligibility criteria: Inclusion Criteria:

* To study at Bandirma Onyedi Eylül University
* Students between the ages of 18-30 years, whose voluntary consent was obtained and who use smartphones

Exclusion Criteria:

* Individuals with musculoskeletal system problems such as fractures of the hand, fingers and upper extremities, rheumatoid disease with evidence of systemic, specific pathological conditions
* Individuals who have undergone any surgical operation related to hand, finger and upper extremity problems
* Individuals who have received hand, finger and upper extremity related physiotherapy and rehabilitation services in less than 6 months
* Individuals with diagnosed psychiatric illness.

Primary outcomes:
measure: Smartphone Addiction Scale-Short Form
timeFrame: May 1, 2024- January 1, 2025
measure: Hand grip strength assessment
timeFrame: May 1, 2024- January 1, 2025
measure: Finger lateral grip strength assessment
timeFrame: May 1, 2024- January 1, 2025
measure: Myoton assessment
timeFrame: May 1, 2024- January 1, 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Balikesir
country: Turkey
facility: Bandırma Onyedi Eylül University
Study officials:
References:
Clinical trial NCT05390190: Radiofrequency in Onychomycosis
Official title: Non Ablative Radiofrequency in the Treatment of Onychomycosis, a Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Onychomycosis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-05-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Onychomycosis is the most common nail disease, representing more than 50% of all onychopathies.

Detailed description: Treatments with antifungals may not be successful due to several factors, including the long time required to apply topical medications, the side effects of systemic drugs, and the application of insufficient medication to the target area. Non-ablative radiofrequency devices can be used to treat onychomycosis without harming the nail matrix cells.

Eligibility criteria: Inclusion Criteria:

* Onychomycosis patients

Exclusion Criteria:

Patients with excessive manual work

Primary outcomes:
measure: Onychomycosis severity index
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05026190: Role of Transrectal-ultrasound in Evaluation of Azoospermia
Official title: Role of Transrectal-ultrasound in Evaluation of Azoospermia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Infertility Due to Azoospermia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-08-30
Enrollment: 50
Sex: MALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Azoospermia is a word meaning to ejaculates with no spermatozoa without a definite underlying cause .1% of men has azoospermia, representing nearly 10 to 15% of all infertile men. The azoospermia is a major concern in our community. There is no actual epidemiological studies to estimate the actual numbers in Egypt. Azoospermia has several classifications, pre-testicular, testicular \& post-testicular cause .The semen analysis is the main investigation done for these patient .The treatment methods range from hormonal therapy to surgery or ICSI . The imaging modalities has developed greatly in the last 3 decades. That it became in several setting as a bedside test or investigation. The main modalities used in azoospermia are scrotal ultrasound, TRUS and MRI. The first TRUS was introduced 1957.


Eligibility criteria: Inclusion Criteria:

* • Adult patients with azoospermia as identified by semen analysis.

  * Age from 18 years to more

Exclusion Criteria:

* • History of operative intervention in the lower urinary tract.

Primary outcomes:
measure: Number of patients With obstructive azoospermia
timeFrame: through study completion ,within average one year.
measure: Number of patient with non obstructive azoospermia
timeFrame: through study completion , within average one year.
measure: Number of patient that will respond to endoscopic treatment
timeFrame: 6 month duration
measure: Number of patients that will need sperm extraction
timeFrame: 9 month duration
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Aziz N. The importance of semen analysis in the context of azoospermia. Clinics (Sao Paulo). 2013;68 Suppl 1(Suppl 1):35-8. doi: 10.6061/clinics/2013(sup01)05.
citation: Gudeloglu A, Parekattil SJ. Update in the evaluation of the azoospermic male. Clinics (Sao Paulo). 2013;68 Suppl 1(Suppl 1):27-34. doi: 10.6061/clinics/2013(sup01)04.
citation: Cocuzza M, Alvarenga C, Pagani R. The epidemiology and etiology of azoospermia. Clinics (Sao Paulo). 2013;68 Suppl 1(Suppl 1):15-26. doi: 10.6061/clinics/2013(sup01)03.
citation: Sihag P, Tandon A, Pal R, Jain BK, Bhatt S, Kaur S, Sinha A. Sonography in male infertility: a look beyond the obvious. J Ultrasound. 2018 Sep;21(3):265-276. doi: 10.1007/s40477-018-0294-5. Epub 2018 Mar 28.
Clinical trial NCT03232190: The Use of an Age-linked App for Parents During and After a NICU Stay
Official title: The Use of an Age-linked Web Application for Parents During and After a NICU Stay in Improving Child Development and Parent Empowerment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Premature Birth
Keywords: prematurity
psychomotor development
parent empowerment
e-health
parental support
post discharge follow-up
Lead sponsor: Ziekenhuis Oost-Limburg
Sponsor class: OTHER
Collaborators: name: KU Leuven
name: TRACE: Centre For Translational Psychological Research
First posted: 2017-07-27
Enrollment: 180
Sex: ALL
Maximum age (years): 32
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The main purpose of the neonatal intensive care unit (NICU) is to optimize the development of the newborn. Preterm children are at greater risk for developmental disorders. On the one hand, this is due to cerebral complications inherent to the prematurity, on the other hand it is related to the very early and therefore vulnerable stage of brain development at the time of the premature birth. The development of the child is also the result of a constant interaction between the infant and its environment, primarily the primary caregiver (i.e. the parents). A premature birth can cause great stress to parents, and there are several obstacles that can make it difficult to handle their child. Therefore, we have developed a web application that supports parents until their child reaches the age of two. By keeping them informed, we hope to make them more confident in their role as parents, and thus facilitate the parent-child interaction. In order to determine whether this form of support has an additional effect on the development of the premature child, we compare two groups of premature infants and a group of non-premature infants.


Eligibility criteria: Inclusion Criteria:

* Premature birth (\< 32 weeks)

Exclusion Criteria:

* The lack of internet access or a personal email account
* Little or no knowledge of Dutch in both parents
* Children with a congenital disease

Primary outcomes:
measure: Change in Bayley-III-NL
timeFrame: 5 months, 1 year, 2 year
measure: Change in DT-P
timeFrame: 2 weeks after birth, 37 weeks PMA, 5 months, 1 year, 2 year, 5 year
measure: Change in EMPO
timeFrame: 2 weeks after birth, 37 weeks PMA, 5 months, 1 year, 2 year, 5 year
measure: WPPSI-III-NL
timeFrame: 5 year
Secondary outcomes:
measure: Change in PNAR
timeFrame: 2 weeks after birth, 37 weeks PMA, 5 months, 1 year, 2 year, 5 year
Other outcomes:
Locations:
city: Genk
country: Belgium
facility: Ziekenhuis Oost-Limburg, Schiepse Bos 6
state: Limburg
Study officials:
affiliation: Ziekenhuis Oost-Limburg
name: Marie-Rose Van Hoestenberghe, MD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00000190: Cocaine in Parotid Saliva, Blood and Urine - 4
Official title: Cocaine in Parotid Saliva, Blood and Urine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cocaine-Related Disorders
Keywords: Cocaine Detection
Parotid Saliva
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 1999-09-21
Enrollment: 0
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to establish the use of parotid saliva as a means of detecting and quantifying cocaine and its metabolites.


Eligibility criteria: Please contact site for information.

Primary outcomes:
measure: Cocaine & benzoylecgonine content in saliva, plasma, & urine
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: James Cornish, M.D.
role: PRINCIPAL_INVESTIGATOR
References: